Title : Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.

Pub. Date : 2015 Sep

PMID : 26135875






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir. Simeprevir KRAS proto-oncogene, GTPase Homo sapiens
2 Persons with hepatitis C virus (HCV) genotype 1a (GT1a) infections harboring a baseline Q80K polymorphism in nonstructural protein 3 (NS3) have a reduced virologic response to simeprevir in combination with pegylated interferon-alfa and ribavirin. Simeprevir KRAS proto-oncogene, GTPase Homo sapiens